Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The GLP-1 medication semaglutide reduces strokes, heart attacks, and death from heart attacks by 20%
Compounded medications are not reviewed or approved by the FDA for safety, efficacy, or manufacturing quality and are not considered FDA-approved
Ozempic, an earlier formulation of semaglutide, was approved by the FDA in 2017 for use in patients with diabetes because it lowers blood glucose
In addition to the STEP trials, real-world studies and independent reviews further support the effectiveness of a variety of GLP-1 receptor agonists for weight management, with weight loss typically ranging from 5% to 15% depending on dose, duration, and adherence.28,29 A retrospective, noninterventional drug utilization cohort study in the United Kingdom evaluated the use of different varieties of liraglutide for weight management purposes.30 Among 604 individuals using Saxenda (liraglutide 3 g) and 4,853 individuals using Victoza (liraglutide 1.2 mg/1.8 mg), most were able to achieve 5% weight loss within 24 weeks.30 Emerging data on tirzepatide has also shown even greater weight reductions (up to 21% over 72 weeks) over other GLP-1s, as well as improved quality of life.31,32 Together, these findings show the support GLP-1s can provide in long-term weight management
Private Insurance Considerations Some employer benefits plans may cover weight loss medications even before provincial formulary inclusion
US$ 21.37
US$ 28.66
US$ 20.15
